Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2017 08h00 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
Novelion Therapeutics’ Subsidiary Launches JUXTAPID® (lomitapide) in Japan
16 déc. 2016 08h35 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first...
CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
17 mars 2016 16h01 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced top line results from its pilot Phase 2 clinical study of MBX-8025 in patients with...
JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 nov. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
16 juin 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2014 09h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
09 avr. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
10 févr. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 janv. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2013 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...